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Definitions
Historically, the terms peripheral arterial 
disease (PAD), peripheral vascular disease, 
and chronic arterial occlusion have been 
used interchangeably. However, the general 
consensus is that PAD is an umbrella term 
used to describe a group of disorders that 
results in structural and functional alteration 
of arteries supplying blood to the viscera and 
limbs (excluding coronary and intracranial 
arteries). 
It is also predominantly recognised as a 
chronic ischaemic condition that leads to 
progressive stenosis and possible occlusion 
of arteries. 
Screening is a process of identifying 
apparently healthy people who may be at 
increased risk for a disease or condition.
For a screening protocol to be most 
effective, the disease process or condition 
being investigated should have the following 
characteristics:
• The disease process or condition should 
be common.
• It should be simple and inexpensive to 
identify the condition in its early stages.
• The condition should have a long latent 
period. 
• The benefits of early treatment or 
secondary prevention should by far 
outweigh delayed intervention. Secondary 




Numerous population-based epidemiological 
studies indicate that the prevalence of 
atherosclerotic PAD in the general population 
ranges from 3% to 14%. There is a significant 
increase in prevalence to 15 - 25% in a 
population >70 years of age (Fig. 1).
Atherosclerosis is the primary aetiological 
process in 80% of patients with PAD.
Clinical presentation
For daily clinical and practical purposes, 
PAD can be classified as asymptomatic 
intermittent claudication or critical limb 
ischaemia. However, for a more detailed 
clinical classification the Fontaine or 
Rutherford classification systems are 
appropriate (Table 1).
Both these classification systems attempt 
to stratify the extent of the atherosclerotic 
burden in the arterial tree with the clinical 
symptoms. They also allow an objective 
way of comparing different clinical sample 
cohorts for study purposes.   
Regardless of the classification system 
used, the findings from population-based 
surveys demonstrate that 50 - 80% of people 
with PAD are asymptomatic or have vague 
atypical leg pain.
The lack of symptomalogy in people 
with obvious occlusive arterial disease can 
be explained by the observation that they 
adapt to their physiological and anatomical 
limitations. They reduce their walking speed, 
adopt a more forgiving sedentary lifestyle 
or are impaired by other comorbidities 
that reduce their ambulatory activity and 
hence mask the underlying PAD symptoms. 
Therefore, the majority of people with PAD do 
not seek medical advice because the disease is 
seemingly benign and asymptomatic.
This clinical presentation is unfortunately 
not a true reflection of the aggressive nature of 
this disease process. Atherosclerosis does not 
selectively affect one arterial vascular bed in 
isolation; it is a generalised multivessel disease 
process. The PARTNERS (PAD Awareness, 
Risk, and Treatment: New Resources for 
Survival) and REACH (Reduction of 
Atherothrombosis for Continued Health) 
surveys have shown a 40 - 60% association 
between PAD, coronary arterial disease 
and cerebrovascular disease (the strongest 
association being between peripheral and 
coronary arterial disease) (Fig. 2).
Natural history of PAD
The association between peripheral, 
coronary and cerebral arterial disease is 
clearly demonstrated when the long-term 
sequelae of PAD are assessed (Fig. 3).  
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Atherosclerosis is the leading cause of coronary, cerebrovascular and peripheral arterial disease (PAD) worldwide. Sedentary lifestyle, stress 
and high-fat/carbohydrate diets have contributed significantly to the rising prevalence of atherosclerosis in most populations. 
Preventive strategies are currently aimed at curbing the socio-economic burden of atherosclerotic disease and its consequences in 
healthcare systems. While myocardial infarction and cerebrovascular accidents are the two leading causes of mortality and long-term 
morbidity, atherosclerotic PAD remains an accurate marker of more generalised disease. Screening programmes for at-risk individuals with 
undiagnosed PAD should therefore be beneficial in preventing future cardiovascular and cerebrovascular events. 
This article reviews the evidence and benefits of selective screening for PAD.












Age (years)Fig. 1. The prevalence of peripheral arterial disease (PAD) (%) by age group (years). (Source: Allison 
MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United 
States. Am J Prev Med 2007;32:328-333.)
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Patients with asymptomatic PAD or atypical 
leg pain comprise 50 - 90% of an affected 
population, and have a good 5-year outcome 
as far as limb morbidity is concerned. 
Unfortunately, 20% of these patients will suffer 
from a non-fatal cardiac or cerebrovascular 
event and 10 - 15% will die from cardiovascular 
complications during the same time period.
The net result is that at 5-year follow-up, 
patients with asymptomatic PAD have at 
least a 20% reduced survival expectation 
than those without PAD.[1] 
There is substantial evidence that risk 
factor and lifestyle modification for PAD 
significantly reduces cardiovascular and 
cerebrovascular events.
• All patients should be encouraged and 
supported with pharmacological agents 
and counselling to stop smoking.
• Those with diabetes mellitus should have 
their haemoglobin A1c (HbA1c) maintained 
around 6%.
• Patients with hypertension should aim 
to maintain a blood pressure equal to or 
below 130/85  mmHg and, if tolerated, 
should use an angiotensin-converting 
enzyme inhibitor (HOPE study).
• Meta-analysis of the major lipid trials 
recommends that the patient’s low-density 
lipoprotein (LDL) be <2.59  mmol/l (for 
every 1  mmol/l decrease in LDL, there 
is a 20% reduction in the incidence of a 
cardiovascular event).
• The daily use of a low-dose antiplatelet 
agent such as aspirin is associated with 
a 25% odds reduction in experiencing 
a cardiovascular event (Antithrombotic 
Trialists’ Collaboration).
• All patients should be encouraged to join 
a supervised walking programme.
Although PAD is a predominately 
asymptomatic condition, it is associated 
with serious long-term complications and 
mortality. Preventive strategies and screening 
are now more than vital. Targeted populations 
should be identified and matched with the 
most appropriate screening tools available.  
Methods to screen for 
PAD
Clinical assessment
This should begin with a detailed history of the 
patient’s claudication symptoms. Numerous 
epidemiological studies have attempted to 
address the efficacy of clinical assessment in 
screening for PAD. A large American study 
by Criqui et. al.[1] concluded that a history 
of claudication was only sensitive in 54% of 
cases and had a 10% positive predictive value 
in accurately diagnosing patients screened for 
PAD. This gross underestimation is due to the 
fact that the aetiologies of leg pain are diverse 
and not all related to arterial disease. Many 
patients were also missed because they were 
asymptomatic.
Physical examination with palpation of 
peripheral foot and wrist pulses has only 
a 50% sensitivity and a positive predictive 
value in confirming the diagnosis of PAD. 
This can be attributed to normal variation 
of arterial anatomy and congenitally absent 
pulses as well as inter-clinician variability.
Bedside investigations 
A meta-analysis by Clarke et al.[2] indicated 
that an inter-arm systolic blood pressure 
Natural history of atherosclerotic lower extremity PAD syndromes
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Fig. 3. The association between peripheral, coronary and cerebral artery disease. (PAD = peripheral arterial 
disease; CV = cerebrovascular; MI = myocardial infarction.) (Source: Hirsch AT, Haskal ZJ, Hertzer NR, et al. 
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extermity, 
renal, mesenteric, and abdominal aortic): Executive summary – a collaborative report from the American 
Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and 
Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/
AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of 
Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and 
Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans-





Fig. 2. The overlap between CAD, CVD and 
PAD. (CAD = coronary artery disease; CVD 
= cerebrovascular disease; PAD = peripheral 
arterial disease.) (Source: Bhatt D, Steg P, 
Ohman E, et al. International prevalence, 
recognition, and treatment of cardiovascular risk 
factors in outpatients with atherothrombosis. 
JAMA 2006;295:180-189.)
Table 1. Fontaine or Rutherford classification systems of peripheral arterial disease
Fontaine classification Rutherford classification
Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild claudication I 1 Mild claudication
IIb Moderate to severe 
claudication
I 2 Moderate claudication
I 3 Severe claudication
III Ischaemic rest pain II 4 Ischaemic rest pain
IV Ulceration or gangrene III 5 Minor tissue loss
III 6 Major tissue loss
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difference of >10 mmHg  is associated with a 
higher mortality and a 2.4-times higher risk 
ratio of PAD.
The most accurate bedside investigation 
for screening for PAD is the ankle brachial 
index (ABI) (Table 2). Fowkes et al.[3] 
validated ABI measurements against 
digital subtraction angiography (DSA) 
to determine its sensitivity, specificity 
and accuracy as a lower extremity PAD 
diagnostic tool. An ABI of <0.9 has a 95% 
sensitivity and a 100% specificity compared 
with a DSA in detecting a 50% arterial 
stenosis and a 96% negative predictive 
value. An ABI of >1.3 is also pathological 
and represents diseased non-compressible 
arteries (most likely calcified). 
There is also evidence that the lower the ABI 
the higher the likelihood of a cardiovasular 
event, as is demonstrated in Fig. 4.
A good clinical assessment and an ABI 
measurement are probably the most sensitive 
modalities with which to screen for PAD.
Who do we screen for 
PAD?
The United States Preventative Service Task 
Force and the American Heart Association 
do not advocate general population screening 
because the prevalence of PAD in asymptomatic 
PAD patients without cardiovascular risk 
factors is insignificant. General population 
screening is not cost-effective and may induce 
unnecessary stress in patients.
The American Heart Association 
recommendations for PAD screening are as 
follows:
• patients <49 years with diabetes and 
another risk factor
• patients >50 years with a history of 
smoking or diabetes
• all patients >65 years
• patients with an abnormal lower extremity 
pulse examination
• patients with atherosclerotic coronary, 
cerebral or renal arterial disease.
They also recommend that all patients 
should have a clinical assessment and an 
ABI as part of the screening. They further 
recommend smoking cessation, lipid 
lowering, antiplatelet therapy, and diabetes 
mellitus and hypertension treatment 
for individuals with asymptomatic lower 
extremity PAD.
The Trans-Atlantic Inter-Society Consensus 
(TASC) II document on the management of 




Recommendation 12 states that ABI 
screening to detect PAD should be 
performed on:
• all patients who have exertional leg 
symptoms 
• all patients between the ages of 50 and 69 
years who have a cardiovascular risk factor 
(particularly diabetes mellitus or smoking) 
• all patients ≥70 years, regardless of risk 
factor status 
• all patients with a Framingham risk score 
of 10 - 20%. 
Based on the evidence briefly discussed 
above, the following approach to screening 
for PAD is suggested:
Why do we need to screen?
• PAD is common in a middle-aged/elderly 
population.
• Asymptomatic PAD and intermittent 
claudication are strongly associated with 
severe cerebrovascular complications and 
a significant mortality rate.
• There is overwhelming evidence that 
with early risk factor modification 
cerebrovascular events can be reduced.
How to screen?
• An ABI of <0.9 is the most sensitive 
method to confirm or exclude PAD. This 
should be done in conjunction with a 
clinical assessment.
Who to screen?
• Individuals who would benefit most from 
a screening programme are those known 
to have traditional atherosclerotic risk 
factors. 
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Fig. 4. The relationship between ankle brachial index and the risk of a cardiovascular event. (ABI = 
ankle brachial index; PAD = peripheral arterial disease; CHD = coronary heart disease.)
Table 2. Interpretation of the ankle brachial index
Value Interpretation
>1.30 Non-compressible
1.00 - 1.29 Normal
0.91 - 0.99 Borderline (equivocal)
0.41 - 0.90 Mild-to-moderate peripheral arterial disease
0.00 - 0.40 Severe peripheral arterial disease
